1
Seiwert Scott, Beigelman Leonid, Buckman Brad, Stoycheva Antitsa Dimitrova, Porter Steven B, Bradford Williamson Ziegler, Serebryany Vladimir: Novel macrocyclic inhibitors of hepatitis c virus replication. Intermune, Seiwert Scott, Beigelman Leonid, Buckman Brad, Stoycheva Antitsa Dimitrova, Porter Steven B, Bradford Williamson Ziegler, Serebryany Vladimir, Mallon Joseph J, November 26, 2009: WO/2009/142842 (25 worldwide citation)

The embodiments provide compounds of the general Formulae I, II, EI, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection an ...


2
BRADFORD WILLIAMSON ZIEGLER, SZWARCBERG JAVIER: Methods of administering pirfenidone therapy, Verfahren zur Verabreichung der Pirfenidontheraphy, Procédés dadministration de la thérapie par la pirfénidone. INTERMUNE, May 25, 2011: EP2324831-A1 (2 worldwide citation)

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.


3

4

5
Bradford Williamson Ziegler, Szwarcberg Javier: Modifying pirfenidone treatment for patients with atypical liver function. Intermune, June 2, 2010: EP2191831-A1

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by adm ...


6
BRADFORD WILLIAMSON ZIEGLER, SZWARCBERG JAVIER: Modification du traitement par pirfénidone pour les patients souffrant d une fonction hépatique atypique, Modifizierung einer Pirfenidonbehandlung für Patienten mit atypischer Leberfunktion, Modifying pirfenidone treatment for patients with atypical liver function. INTERMUNE, September 19, 2012: EP2500019-A1

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by adm ...


7
BRADFORD WILLIAMSON ZIEGLER, SZWARCBERG JAVIER: Modification du traitement par pirfénidone pour les patients souffrant d une fonction hépatique atypique, Modifizierung einer Pirfenidonbehandlung für Patienten mit atypischer Leberfunktion, Modifying pirfenidone treatment for patients with atypical liver function. INTERMUNE, October 3, 2012: EP2505199-A1

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by adm ...


8

9
BRADFORD WILLIAMSON ZIEGLER: Method of providing pirfenidone therapy to a patient, Verfahren zur Bereitstellung einer Pirfenidontherapie an einem Patienten, Procédé permettant dadministrer une thérapie par le pirfenidone à un patient. INTERMUNE, June 29, 2011: EP2338489-A1

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administrat ...


10
BRADFORD WILLIAMSON ZIEGLER, SZWARCBERG JAVIER: Pirfenidone treatment for patients with atypical liver function, Pirfenidone Behandlung für Patienten mit atypischer Leberfunktion, Traitement avec le pirfenidone de patients avec fonctions hépatique atipique. INTERMUNE, July 13, 2011: EP2343070-A1

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by adm ...